US EditionKiwi drug agency Pharmac escapes US scrutiny over prices
- The United States pharmaceutical lobby has urged President Trump to impose tariffs on Australia's Pharmaceutical Benefits Scheme , claiming it harms American profits and exports.
- In 2023-24, the PBS listed 930 different medicines and cost the Australian government AUD 17.7 billion, making treatments affordable for patients.
- Prime Minister Anthony Albanese defended the PBS, asserting that it is vital for public health and not negotiable.
- Health Minister Mark Butler affirmed that the PBS would not change due to advocacy from any other country, rejecting U.S. Concerns.
19 Articles
19 Articles
‘Thousands of dollars more’: US bid to hurt sick Aussies
Australians would pay hundreds of dollars more for medicines like insulin and asthma inhalers under a US drug makers’ push to unravel the Pharmaceutical Benefits Scheme, as Anthony Albanese declares the subsidy program is “not for sale”.
US Big Pharma Lobbies Trump to Tariff Australian Drug Imports
Health Minister Mark Butler has sought to reassure Australians that there won’t be any changes to the nation’s $18 billion Pharmaceutical Benefits Scheme (PBS) following calls for punitive tariffs on Australian medications imported by the United States. U.S. pharmaceutical companies, via the Pharmaceutical Research and Manufacturers of America (PhRMA), have expressed concern about Australia’s PBS, which subsidises the cost of medicine so that re…
Coverage Details
Bias Distribution
- 38% of the sources lean Left, 38% of the sources lean Right
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
